System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish

PubMed: 40034365 DOI: 10.1177/25424823241284464

A systematic study of molecular targets of cannabidiol in Alzheimer's disease.

J Alzheimers Dis Rep 8(1):1339-1360

Authors: Nil Patil, Khushalika Patil, Mukul Jain, Arifullah Mohammed, Alpa Yadav, Parmdeep Singh Dhanda, Chittaranjan Kole, Kirtan Dave, Prashant Kaushik, Mohammad Khairul Azhar Abdul Razab, Zulhazman Hamzah, Norazlina Mat Nawi

Affiliations

  • Cell & Developmental Biology Lab, Research & Development Cell, Parul University, Vadodara, Gujarat, India.
  • Department of Life Sciences, Parul Institute of Applied Sciences, Parul University, Vadodara, Gujarat, India.
  • Faculty of Earth Science, Universiti Malaysia Kelantan, Jeli, Kelantan, Malaysia.
  • Department of Agriculture Science, Faculty of Agro-Based Industry, Universiti Malaysia Kelantan, Jeli, Kelantan, Malaysia.
  • Department of Botany, Indra Gandhi University, Meerpur, Rewari, India.
  • Department of Biochemistry, Punjab Agriculture University, Ludhiana, Punjab, India.
  • The Neotia University, Sarisha Jhinga, West Bengal, India.
  • Bioinformatics Laboratory, Research & Development Cell, Parul University, Vadodara, Gujarat, India.
  • Chaudhary Charan Singh Haryana Agricultural University, Hisar, India.
  • Medical Radiation Programme, School of Health Sciences, Universiti Sains Malaysia, Health Campus, Kubang Kerian, Kelantan, Malaysia.
  • Department of Nuclear Medicine, Radiotherapy & Oncology, School of Medical Sciences, Universiti Sains Malaysia, Health Campus, Kubang Kerian, Kelantan, Malaysia.

Abstract

Background

Alzheimer's disease (AD) is a prevalent, incurable, and chronic neurodegenerative condition characterized by the accumulation of amyloid-β protein (Aβ), disrupting various bodily systems. Despite the lack of a cure, phenolic compounds like cannabidiol (CBD), a non-psychoactive component of cannabis, have emerged as potential therapeutic agents for AD.

Objective

This systematic review explores the impact of different types of cannabidiol on AD, unveiling their neuroprotective mechanisms.

Methods

The research used PubMed, Scopus, and Web of Science databases with keywords like "Alzheimer's disease" and "Cannabidiol." Studies were evaluated based on title, abstract, and relevance to treating AD with CBD. No restrictions on research type or publication year. Excluded were hypothesis papers, reviews, books, unavailable articles, etc.

Results

Microsoft Excel identified 551 articles, with 92 included in the study, but only 22 were thoroughly evaluated. In-vivo and in-silico studies indicate that CBD may disrupt Aβ, reduce pro-inflammatory molecule release, prevent reactive oxygen species formation, inhibit lipid oxidation, and counteract Aβ-induced increases in intracellular calcium, thereby protecting neurons from apoptosis.

Conclusions

In summary, the study indicates that CBD and its analogs reduce the production of Aβ. Overall, these findings support the potential of CBD in alleviating the underlying pathology and symptoms associated with AD, underscoring the crucial need for further rigorous scientific investigation to elucidate the therapeutic applications and mechanisms of CBD in AD.

MeSH

Transient Receptor Potential Channels, Alzheimer Disease, Research, Therapeutics, Cannabidiol